Lacerta Therapeutics, Inc.

Industry

  • Services
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Macromolecule
  • Biotechnology
    • Drug Discovery Technologies
    • Synthesis Technologies, Production Processes
    • Gene Therapy, Cell Therapy
See more in Biomedtracker

Latest on Lacerta Therapeutics, Inc.

Scrip

Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies

 
• By Joseph Haas and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ovid Taps Gensaic’s Approach To Neurolo

Scrip

Juggling Gene Therapies: Sarepta's Focus Grows, With Many Balls In The Air

 
• By Jessica Merrill

Sarepta Therapeutics Inc. 's micro-dystrophin gene therapy program for Duchenne muscular dystrophy (DMD) is getting a lot of attention from investors as a near-term potential cure for the progressive

Scrip

Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing

 
• By Joseph Haas and Kevin Grogan

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent licensing and alliance transactions – mergers an

Scrip

Deal Watch, Licensing Focus: Roche, Sanofi Exit Ongoing Anticalin Development Efforts With Pieris

 
• By Joseph Haas and Eleanor Malone

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in